855-91-4 Usage
Uses
Used in Pharmaceutical Industry:
N4-Acetylsulfaphenazole is used as an intermediate in the synthesis of Sulfaphenazole for its pharmacological applications. It is particularly valuable in the development of drugs that target the CYP2C9 enzyme, which is involved in the metabolism of various drugs and other xenobiotics. By inhibiting this enzyme, Sulfaphenazole can help regulate the metabolic processes and improve the efficacy and safety of certain medications.
Used in Drug Metabolism Research:
N4-Acetylsulfaphenazole is used as a research tool in the study of drug metabolism and the role of the CYP2C9 enzyme in the process. Understanding the interactions between N4-acetylsulfaphenazole, its derivatives, and the enzyme can provide valuable insights into the development of new drugs and the optimization of existing ones, ultimately leading to better therapeutic outcomes for patients.
Used in Drug Interaction Studies:
N4-Acetylsulfaphenazole is used in studies investigating drug-drug interactions, particularly those involving the CYP2C9 enzyme. By examining the effects of N4-acetylsulfaphenazole on the enzyme's activity, researchers can better understand how different medications may interact with each other and potentially cause adverse effects or alter the efficacy of the drugs involved. This knowledge is essential for the safe and effective use of medications in clinical practice.
Check Digit Verification of cas no
The CAS Registry Mumber 855-91-4 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 8,5 and 5 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 855-91:
(5*8)+(4*5)+(3*5)+(2*9)+(1*1)=94
94 % 10 = 4
So 855-91-4 is a valid CAS Registry Number.
InChI:InChI=1/C17H16N4O3S/c1-13(22)19-14-7-9-16(10-8-14)25(23,24)20-17-11-12-18-21(17)15-5-3-2-4-6-15/h2-12,20H,1H3,(H,19,22)
855-91-4Relevant academic research and scientific papers
The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition
Chen, Hui,Wang, Bin,Li, Peng,Yan, Hong,Li, Gang,Huang, Haihong,Lu, Yu
supporting information, (2021/03/26)
In this study, a series of sulfonamide compounds was designed and synthesized through the systematic optimization of the antibacterial agent sulfaphenazole for the treatment of Mycobacterium tuberculosis (M. tuberculosis). Preliminary results indicate that the 4-aminobenzenesulfonamide moiety plays a key role in maintaining antimycobacterial activity. Compounds 10c, 10d, 10f and 10i through the optimization on phenyl ring at the R2 site on the pyrazole displayed promising antimycobacterial activity paired with low cytotoxicity. In particular, compound 10d displayed good activity (MIC = 5.69 μg/mL) with low inhibition of CYP 2C9 (IC50 > 10 μM), consequently low potential risk of drug-drug interaction. These promising results provide new insight into the combination regimen using sulfonamide as one component for the treatment of M. tuberculosis.
